hormone receptor-positive

fda breast cancer treatment verzenio

FDA approves new breast cancer treatment

On Sept. 28, the U.S. Food and Drug Administration (FDA) approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2…

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Poll

Preferred way to get content

What is your preferred way to consume healthcare content?

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.